HC Wainwright & Co. Maintains Buy on Viracta Therapeutics, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on Viracta Therapeutics (NASDAQ:VIRX) but has reduced the price target from $10 to $4.
January 05, 2024 | 11:17 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Viracta Therapeutics' price target has been lowered from $10 to $4 by HC Wainwright & Co., although the Buy rating is maintained.
The reduction in price target by HC Wainwright & Co. suggests a reassessment of Viracta Therapeutics' future prospects, which could lead to a negative short-term impact on the stock price. However, maintaining a Buy rating indicates the analyst still sees long-term value in the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100